J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
|
|
- Tyler Cummings
- 5 years ago
- Views:
Transcription
1 VOLUME 26 NUMBER 1 JANUARY JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Michael J. Sundborg, G. Scott Rose, Peter G. Rose, Stephen C. Rubin, Franco Muggia, and William P. McGuire From the Department of Obstetrics and Gynecology, Gynecologic Oncology, Brooke Army Medical Center, Ft Sam Houston, TX; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Walter Reed Army Medical Center, Washington, DC; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo; Division of Medical Oncology, New York University Medical Center, New York, NY; Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH; Department of Gynecologic Oncology, University of Pennsylvania Cancer Center, Philadelphia, PA; and Harry and Jeanette Weinberg Cancer Institute, Franklin Square Hospital Center, Baltimore, MD. Submitted June 27, 2007; accepted September 25, 2007; published online ahead of print at on November 19, Supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (Grant No. CA 27469) and the Gynecologic Oncology Group Statistical Office (Grant No. CA 37517). Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Corresponding author: G. Larry Maxwell, MD, Division of Gynecologic Oncology, Walter Reed Army Medical Center, Rm 6743, Bldg 2, 6900 Georgia Ave, Washington, DC 20015; george.maxwell@na.amedd.army.mil by American Society of Clinical Oncology X/08/ /$20.00 DOI: /JCO A B S T R A C T Purpose To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC). Patients and Methods A retrospective review of 360 patients with International Federation of Gynecology and Obstetrics stage IV EOC who underwent primary surgery followed by six cycles of intravenous platinum/ paclitaxel was performed. A proportional hazards model was used to assess the association of potential prognostic factors with progression-free survival (PFS) and overall survival (OS). Results The median PFS and OS for this group of stage IV ovarian cancer patients was 12 and 29 months, respectively. Multivariate regression analysis revealed that histology, malignant pleural effusion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variables. Whereas patients with microscopic residual disease had the best outcome, patients with 0.1 to 1.0 cm residual disease and patients with 1.1 to 5.0 cm residual disease had similar PFS and OS. Patients with a residual size more than 5 cm had a diminished PFS and OS when compared with all other groups. Median OS for microscopic, 0.1 to 5.0 cm, and more than 5.0 cm residual disease was 64, 30, and 19 months, respectively. Conclusion Patients with more than 5 cm residual disease have the shortest PFS and OS, whereas patients with 0.1 to 1.0 and 1.1 to 5.0 cm have similar outcome. These findings suggest that ultraradical cytoreductive procedures might be targeted for selected patients in whom microscopic residual disease is achievable. Patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytoreduction. J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION Epithelial ovarian cancer (EOC) is the leading cause of death among gynecologic malignancies in the United States. 1 Approximately 15% of EOC is diagnosed as International Federation of Gynecology and Obstetrics stage IV disease. Overall, median survival for patients with stage IV disease is approximately 15 to 23 months, 2-5 with an estimated 5-year survival of 20%. 2,5 Previous studies of prognostic factors in stage IV EOC have focused on surgical cytoreduction and the association between residual disease size and clinical outcome. 2,3,5-8 Unfortunately, interpretation is difficult because of nonuniform study design and analysis, and the retrospective nature of the studies. Consequently, controversies abound on the optimal management of stage IV EOC, specifically in the surgical management of these patients. Many of the studies have used less than 1 cm or less than 2 cm in defining optimal residual, but others have used from less than 0.5 cm to less than 3.0 cm. Many of the previous studies also have included patients receiving adjuvant chemotherapy other than platinum and paclitaxel-based regimens that are considered to be a contemporary standard. Finally, many of the studies have pooled both stage III and IV patients in the analysis. These two stages represent two different groups of patients warranting more individualized treatment decisions. 9 During the last 13 years, the Gynecologic Oncology Group (GOG) has conducted four 83
2 Winter et al randomized phase III trials that included patients with stage IV EOC treated with intravenous chemotherapy consisting of a platinum-based agent and paclitaxel after primary surgical cytoreduction. We used this large and similarly treated group of patients with stage IV EOC to perform a retrospective analysis of the pooled data aimed at identifying independent prognostic factors and evaluating the clinical impact of residual disease size, in particular, after surgical cytoreduction. PATIENTS AND METHODS The current study was a retrospective review of data from patients with stage IV EOC treated with platinum and paclitaxel combination chemotherapy on one of four prospective randomized clinical trials conducted by the GOG (Appendix, online only): protocols 111, , , 12 and Patients enrolled onto the experimental arm of GOG 111 and the control arms of GOG 132, 152, and 162 were treated with primary surgical cytoreduction and six cycles of a 24-hour infusion of intravenous paclitaxel 135 mg/m 2, followed by intravenous cisplatin 75 mg/m 2. We also included the experimental arms of GOG 152 and 162 because each of these trials demonstrated statistically equivalent clinical outcomes between the control and experimental arms and both contained a platinum and paclitaxel-based regimen. Table 1 lists the treatment regimens from each protocol that were included in this study. Details regarding eligibility criteria, treatment, and outcome for each particular study have been published previously. Patients provided written informed consent consistent with all federal, state, and local requirements before receiving protocol therapy. The primary end points for all four studies were progression-free survival (PFS) and overall survival (OS). PFS was calculated from the date of study enrollment to the date of disease recurrence (confirmed on physical, serologic, or radiologic examination), death, or most recent follow-up visit. OS was calculated from the date of study enrollment to the date of death or last contact. Laboratory and clinical data were collected at specified intervals per protocol. In addition to GOG surgical reporting forms, all operative, radiology, and pathology reports were reviewed to abstract specific data regarding surgical procedures, stage IV disease site(s), largest diameter of intraoperative disease and postoperative residual disease (intra- and extraperitoneal), and site of largest diameter of postoperative residual disease. Of note, visible gross tumor residual size less than 1.0 cm was recorded in 0.1-cm increments based on operative reports and GOG surgical reporting forms. All hospital and treatment summaries were reviewed to collect data on length of hospital stay and postoperative complications. Complications included length of stay more than 15 days; unplanned intensive care unit admission; transfusion of more Table 1. GOG Treatment Protocols and Study Populations GOG Protocol No. Patient Eligibility Treatment Regimen 111 Suboptimal ( 1 cm residual) stage III/IV EOC 132 Suboptimal ( 1 cm residual) stage III/IV EOC 152 Suboptimal ( 1 cm residual) stage III/IV EOC 162 Stage III ( 1cmRP; 1cm IP residual) and stage IV EOC/PSPC and cisplatin 75 mg/m 2 for 6 cycles and cisplatin 75 mg/m 2 for 6 cycles and cisplatin 75 mg/m 2 for 6 cycles interval debulking 24- or 96-hour infusion, cisplatin 75 mg/m 2 for 6 cycles No. of Stage IV Patients Abbreviations: GOG, Gynecologic Oncology Group; EOC, epithelial ovarian cancer; PSPC, papillary serous carcinoma; RP, retroperitoneal sites; IP, intraperitoneal sites. Includes 4 patients with PSPC. than 4 units of packed red cells; estimated blood loss of more than 2,000 ml; GI anastomotic leaks; urinary tract injury; neural injury; vascular injury; and unplanned return to the operating room, readmission, or death within 30 days of primary surgery. Clear-cell carcinomas were assigned grade 3. Baseline performance status (PS) before initiating chemotherapy was defined according to GOG criteria (0 normal activity; 1 symptomatic, fully ambulatory; 2 symptomatic, in bed less than 50% of the time). The Cox proportional hazards model was used to identify the independent prognostic factors as well as to estimate their effects on PFS and OS adjusted for covariates. Kaplan-Meier survival curves based on residual disease status and other clinical factors were calculated and compared using the Table 2. Patient Demographic and Clinical Characteristics (N 360) Characteristic No. of Patients % Age, years Median 58.8 Range Race White Black Other GOG performance status Tumor grade Serous Endometrioid Mucinous Clear cell Adenocarcinoma unspecified Mixed epithelial Undifferentiated Other Residual size, cm Median 3.0 Range (no visible) Distant Parenchymal liver Pleural effusion Subcutaneous Others Multiple sites Abbreviation: GOG, Gynecologic Oncology Group. 84 JOURNAL OF CLINICAL ONCOLOGY
3 Stage IV Ovarian Cancer log-rank test. All statistical tests were two tailed with a significance level set at 5%. All statistical analyses were performed on Statistical Analysis Software, version 9.1 (SAS Institute, Cary, NC). RESULTS Data from the 360 patients with stage IV invasive EOC who underwent primary surgical cytoreduction followed by paclitaxel/platinum chemotherapy while participating in one of four GOG clinical trials (Table 1) were analyzed for the present study. Table 2 lists the demographic and clinical characteristics of the study population. The median age of patients was 59 years (range, 24 to 86 years) and the majority were white (88%), with a pretreatment GOG performance status of 0 to 1 (83%). Clinically, 74% of them were serous cell type and 62% were classified as tumor grade 3. The median size of largest residual disease (intra- and extraperitoneal) was 3.0 cm; only 8% of patients had microscopic (no visible) disease and almost one fourth had more than 5 cm of residual disease. Malignant pleural effusion was the most common site of stage IV disease (48%). Univariate Analysis Three hundred four recurrences and 320 deaths were identified within a median follow-up period of 28 months. The median PFS was Table 3. Median PFS and OS by Patient Characteristics No. of PFS OS Characteristic Patients Median (months) P Median (months) P Age group, years Race White Black Other GOG performance status Serous Endometrioid Clear cell/mucinous Mixed epithelial Others Tumor grade Tumor residual, cm Incremental disease residual 0.0 (no visible) Categorical disease residual 0.0 (no visible) Distant Parenchymal liver Pleural effusion Subcutaneous/other Multiple sites Abbreviations: PFS, progression-free survival; OS, overall survival; GOG, Gynecologic Oncology Group. 85
4 Winter et al 12.3 months (95% CI, 11.3 to 13.2 months). Forty-eight percent of patients had disease progression within the first year and only 19% remained progression free by the end of the second year. Univariate analysis, which included age, race, GOG PS, histology, tumor grade, residual disease size, and stage IV sites (Table 3), revealed that residual disease, multiple stage IV sites, and mucinous/clear cell histology were associated with poor PFS and OS (P.05). A significant association between liver metastases and decreased OS was also identified (P.05). Other variables, including performance status, tumor grade, age, and race, did not appear to have a significant association with clinical outcomes. The effects of residual disease were assessed in 1-cm increments from microscopic disease to more than 6 cm. Gross residual disease was found to be associated with decreased PFS and OS. The correlation between residual disease size and median PFS and OS seemed to segregate into three categories: microscopic, 0.1 to 5 cm, and more than 5 cm of residual disease. Multivariate Regression Analysis All variables considered as potential prognostic factors (ie, age, race, GOG PS, tumor grade, histology, residual tumor size, and stage IV site) were included in a Cox proportional hazards multivariate regression model for preassessment. Age, race, GOG PS, and tumor grade were excluded secondary to lack of independent association with clinical outcomes. The final model included three independent variables: histology, stage IV site, and residual disease size. These results are listed in Table 4. When patients with microscopic disease were used as the referent, the adjusted hazard ratio (HR) for disease progression in patients with 0.1 to 5.0 and more than 5.0 cm was 2.09 (95% CI, 1.36 to 3.21; P.0008) and 2.95 (95% CI, 1.85 to 4.69; P.0001), respectively, and the relative risk between more than 5.0 cm and 0.1 to 5.0 cm residual disease size was 1.41 (95% CI, 1.08 to 1.84; P.01). The overall survival results were similar to those shown for PFS. The adjusted HR for death in patients with 0.1 to 5.0 and more than 5.0 cm was 1.87 (95% CI, 1.18 to 2.96; P.008) and 2.73 (95% CI, 1.66 to 4.49; P.0001), respectively, and the group with more than 5.0 cm also showed significantly increased risk for death compared with the group with 0.1 to 5.0 cm (HR 1.46; 95% CI, 1.11 to 1.92; P.006). Analysis of the data was also performed using both 1 and 2 cm in defining optimal cutoff residual tumor size. Our results confirmed data reported in previous investigations using these thresholds for optimal disease in their analysis (2 to 3; 5; 7 to 8 cm). Though these analyses using 1- and 2-cm cutoffs were suggestive of this relationship, the association between tumor residual size and clinical outcome was best illustrated by the three-tier classification as delineated in the univariate analysis. Furthermore, the prognosis for those patients with residual size of 0.1 to 1.0 cm and 1.0 to 5.0 cm was comparable (HR 1.08; 95% CI, 0.80 to 1.45; P.61 for PFS v HR 0.95; 95% CI, 0.70 to 1.29; P.73 for OS using residual size of 0.1 to 1.0 cm as the referent). Patients with residual tumor more than 5.0 cm had an increased risk of disease progression (HR 1.56; 95% CI, 1.20 to 2.03, P.0008) and death (HR 1.57; 95% CI, 1.20 to 2.05; P.001) when compared with all other patients. Of note, there was no difference in outcomes if the suboptimal disease was found at intra- and/or extraperitoneal (or intraparenchymal) sites (data not shown). Only those with multiple stage IV disease sites had a borderline increased risk of disease progression (HR 1.54; 95% CI, 0.99 to 2.40; Prognostic Factor Table 4. Multivariate Analysis of Prognostic Factors PFS HR 95% CI P HR 95% CI P Serous Endometrioid to to Clear cell/mucinous to to Mixed epithelial to to Other to to Distant Parenchymal liver to to Pleural effusion to to Subcutaneous/other to to Multiple sites to to Tumor residual, cm Optimal: microscopic residual 0.0 (no visible) to to to to to to Optimal: 1.0 cm residual to to Optimal: 2.0 cm to to Abbreviations: PFS, progression-free survival; OS, overall survival. OS 86 JOURNAL OF CLINICAL ONCOLOGY
5 Stage IV Ovarian Cancer P.05). Patients with parenchymal liver metastases, pleural effusions, or multiple stage IV disease sites experienced decreased survival (HR 1.68; 95% CI, 1.07 to 2.63; P.02 v HR 1.73; 95% CI, 1.17 to 2.54; P.006 v HR 2.24; 95% CI, 1.40 to 3.59; P.0008, respectively) relative to patients with distant site disease (eg, supraclavicular/axillary lymphadenopathy, parenchymal lung metastases, mediastinal adenopathy, and distal vaginal/perineal metastases). Mucinous/clear cell tumors were predictive of increased disease progression (HR 2.34; 95% CI, 1.43 to 3.85; P.0008) and poor survival (HR 2.34; 95% CI, 1.40 to 3.92; P.001). PFS and OS based on residual disease size are also illustrated in Figure 1. The overall median PFS and OS for stage IV patients were 12 and 28 months, respectively. The estimated 3-year PFS and OS were 13% and 38%, respectively. The median PFS (Fig 1A) for patients with microscopic residual disease (20 months) was superior to that in patients with any amount of gross residual disease. Although the median PFS was 13 months for patients with 0.1 to 1.0 and 1.1 to 5.0 cm of residual disease, patients with more than 5.0 cm of residual disease had a shorter median PFS compared with all other groups (8.5 months). Similar results were seen with OS (Fig 1B), where the median OS for patients with microscopic residual disease (64 months) was superior to that in patients with any amount of gross residual disease. Patients with 0.1 to 1.0 and 1.1 to 5.0 cm of residual had statistically similar median OS: 29 and 31 months, respectively. Patients with more than 5.0 cm of residual disease had a shorter median OS compared with all other groups (19 months). These associations were consistent over the time period of the protocols included in this study. When evaluating the association of clinicopathologic factors with residual disease status, there was no difference between the residual disease groups and demographic, clinical, and pathologic factors (Table 5). Our data also revealed that variations in the size of residual tumor (ie, microscopic, 0.1 to 5.0, and 5 cm residual disease) were not associated with an increased risk of perioperative complications (ie, length of stay 15 days, estimated blood loss 2,000 ml, transfusion 4 units, urinary tract infection, neural injury, vascular injury, unplanned admission to the intensive care unit, unplanned readmission 30 days, unplanned return to OR 30 days, or death 30 days). In addition, the stage IV site did not seem to have significant association with residual disease group distributions. DISCUSSION A PFS Probability B OS Probability Time on Study (months) Time on Study (months) 0 cm cm cm > 5.0 cm 0 cm cm cm > 5.0 cm Fig 1. Kaplan-Meier estimate of (A) progression-free survival (PFS) and (B) overall survival (OS) by residual tumor size. Although several series have evaluated prognostic factors in stage IV EOC, 2-8,14 to our knowledge, this study represents the largest investigation of stage IV EOC patients reported to date. Only women receiving adjuvant chemotherapeutic regimens that consisted of platinum with paclitaxel were included in this analysis to provide conclusions that would be applicable to patient care in a contemporary practice setting. The strength of this study lies in the large size and similarity of the population. Adherence to strict protocol regimens of primary surgical assessment and cytoreduction of disease burden and postoperative therapy provides enhanced statistical power to detect independent variables predictive of poor outcome and a precise estimation of the magnitude of the effect while controlling for confounding influences. Variation in the method of defining optimal residual disease also has led to the variable degree of association between residual disease size and clinical outcome. Investigators using 1 cm as the defining size for optimal residual disease have reported median survival of 38 months, compared with 10 months for those with suboptimal residual disease size (P.05). 3 Curtin et al 2 used 2 cm as a threshold for defining optimal residual disease and also observed an improved median survival in stage IV patients with less than 2 cm residual disease (40 months) compared with those with 2 cm residual disease (18 months; P.01). Using multivariate analysis, we evaluated the data using either 1 or 2 cm as a threshold in defining optimal disease. The risk of recurrence was almost 50% greater among patients with more than 1 cm residual disease compared with patients with less than 1 cm residual disease, and overall survival was also significantly lower in suboptimally debulked patients defined using this threshold (HR 1.30; 95% CI, 1.00 to 1.59; P.05). Analysis of the data using less than 2 cm as a defining measure of optimal residual disease revealed that patients with suboptimal residual disease size had a decreased PFS but there was no significant association with decreased OS. Although our initial analysis had confirmed the historic data, we subsequently chose to evaluate the data without any preconceived plans for dichotomization at a previously reported threshold 87
6 Winter et al Characteristic Table 5. Patient Characteristics by Residual Disease Residual Disease (cm) 0.0 (no visible) No. % No. % No. % Age group, years Race White Black Other GOG performance status Serous Endometrioid Clear cell/mucinous Mixed epithelial Other Tumor grade Distant Parenchymal liver Pleural effusion Subcutaneous/other Multiple sites Abbreviation: GOG, Gynecologic Oncology Group. P of optimal residual. Median PFS and OS were noted to cluster into three groups based on size of residual disease: microscopic (0 cm), 0.1 to 5.0 cm, and more than 5 cm. Hazard proportions analysis confirmed that both PFS and OS were significantly worse in patients with either 0.1 to 5 cm or more than 5 cm compared with patients with microscopic disease (Table 4). In the illustration of survival data, we chose to show survival for microscopic disease, 0.1 to 1.0 cm, 1.1 to 5.0 cm, and more than 5 cm in an effort to further evaluate the outcome among patients with 0.1 to 1.0 cm and 1.1 to 5 cm residual disease. Neither disease progression nor survival was different between patients with 0.1 to 1.0 cm and those with 1.1 to 5.0 cm of residual disease. Patients with more than 5 cm of residual disease had both worse PFS and OS compared with any other group (Fig 1). Our data revealed that variations in the degree of size of residual tumor were not associated with an increased risk of complications, suggesting that even with potential selection bias, there does not seem to be an increased level of mortality associated with cytoreduction to microscopic disease. Inconsistent intraoperative descriptions of disease size and distribution before and after cytoreduction prevented us from more precisely assessing the proportion of tumor removed as a result of surgical cytoreduction for all of the patients. However, only 19, 18, and five patients had 50%, 25%, and 1% of the tumor burden removed, respectively, based on GOG surgical reporting forms. Thus, almost 90% of patients underwent removal of more than 50% of their tumor burden, suggesting that significant proportions of disease volume were removed as a result of cytoreductive efforts. Although this study did not evaluate prospectively the association of surgical cytoreduction with survival, the data still provide provocative evidence to suggest that the traditional surgical approach of primary cytoreduction to less than 1 cm in stage IV disease should be re-evaluated in an era of platinum and paclitaxel-based chemotherapy. For instance, patients with more than 5 cm of disease may benefit from surgery that is tailored according to whether the patient can undergo cytoreduction to microscopic disease or 0.1 to 5 cm residual disease. Ultraradical procedures might be justified in cases in which the patient can be completely debulked to microscopic disease. More tempered surgical cytoreduction aimed at reducing the size of the largest residual implant to less than 5 cm may be considered for those individuals in whom resection to microscopic disease cannot be achieved safely, given that the patient s outcome seems to be similar irrespective of whether they undergo resection to either 0.1 to 1.0 or 1.1 to 5.0 cm. Patients presenting with 0.1 to 5 cm disease size might be considered for a diagnostic surgical procedure, such as laparoscopy, hand-assisted laparoscopy, or minilaparotomy, in an attempt to best assess resectability. Patients with disease that is considered safely resectable to microscopic disease may then undergo laparotomy 88 JOURNAL OF CLINICAL ONCOLOGY
7 Stage IV Ovarian Cancer and complete surgical cytoreduction. Median OS of patients with microscopic residual disease in the current study (64 months) compares favorably with stage III patients with microscopic residual disease (72 months) from our previous study. 15 Possible alternatives (eg, neoadjuvant therapy, interval debulking, and so on) would be reserved for those in whom microscopic cytoreduction is not deemed possible because their outcome appears uninfluenced by the extent of cytoreduction that falls short of microscopic residual disease. Currently, preoperative identification of patients most likely to achieve cytoreduction to microscopic disease is limited on the basis of current radiologic imaging and laboratory testing. 9,16,17 Furthermore, some patients with stage IV disease are diagnosed only postoperatively by imaging or malignant pleural cytology. Therefore, some initial form of surgery would be recommended in all stage IV ovarian cancer patients who are medically fit to undergo surgery. Whether surgical cytoreductive effort, tumor biology, or a combination of both is more predictive of tumor residual remains to be determined. Nonetheless, residual tumor size has a significant association with PFS and OS among patients with stage IV EOC. Previous studies demonstrating improved outcome in patients with small postoperative residual tumor size 6-9 have prompted many surgeons to adopt aggressive surgical practice patterns in the cytoreduction of metastatic ovarian cancer. However, there has not been a prospective randomized trial comparing surgical cytoreductive efforts among advancedstage EOC patients performed to date. Until more definitive phase III data are made available, our current findings may assist the gynecologic oncologist in his/her approach at cytoreduction in EOC patients with stage IV disease. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a U are those for which no compensation was received; those relationships marked with a C were compensated. For a detailed description of the disclosure categories, or for more information about ASCO s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors. Employment or Leadership Position: None Consultant or Advisory Role: Franco Muggia, Bristol-Myers Squibb (C); William P. McGuire, Unither (C), GlaxoSmithKline (C), Genetech (C), Novartis (C) Stock Ownership: None Honoraria: Franco Muggia, Ortho Biotech; William McGuire, GlaxoSmithKline, Novartis Research Funding: William P. McGuire, GlaxoSmithKline Expert Testimony: None Other Remuneration: None AUTHOR CONTRIBUTIONS Conception and design: William E. Winter III, G. Larry Maxwell, G. Scott Rose Financial support: G. Scott Rose Administrative support: G. Scott Rose Provision of study materials or patients: William E. Winter III, Peter G. Rose, Stephen C. Rubin, William P. McGuire Collection and assembly of data: William E. Winter III, Michael J. Sundborg Data analysis and interpretation: William E. Winter III, G. Larry Maxwell, Chunqiao Tian, Franco Muggia, William P. McGuire Manuscript writing: William E. Winter III, George Larry Maxwell, Chunqiao Tian, G. Scott Rose, Peter G. Rose, Franco Muggia, William P. McGuire Final approval of manuscript: William E. Winter III, George Larry Maxwell, G. Scott Rose, Peter G. Rose, Stephen C. Rubin, Franco Muggia, William P. McGuire REFERENCES 1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, CA Cancer J Clin 56: , Curtin JP, Malik R, Venkatraman ES, et al: Stage IV ovarian cancer: Impact of surgical debulking. Gynecol Oncol 64:9-12, Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72: , Repetto L, Chiara S, Pace M, et al: Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. Tumori 76: , Akahira JI, Yoshikawa H, Shimizu Y, et al: Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol Oncol 81: , Goodman HM, Harlow BL, Sheets EE, et al: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 46: , Liu PC, Benjamin I, Morgan MA, et al: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64:4-8, Munkarah AR, Hallum AV, Morris M, et al: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64:13-17, Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: , McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 18: , Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: , Spriggs DR, Brady MF, Rubin S, et al: Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25: , Scholz HS, Benedicic C, Haas J, et al: Stage IV ovarian cancer: Prognostic factors and survival beyond 5 years. Anticancer Res 21: , Winter WE III, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25: , Memarzadeh S, Lee SB, Berek JS, et al: CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13: , Chi DS, Venkatraman ES, Masson V, et al: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77: , 2000 Appendix The Appendix is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader ). 89
J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter
More informationCA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers
CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study Chunqiao Tian, MS 1, Maurie Markman,
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationBACKGROUND. The objective of this study was to determine the impact of malignant
1397 The Clinical Significance of Malignant Pleural Effusions in Patients with Optimally Debulked Ovarian Carcinoma Ram Eitan, M.D. Douglas A. Levine, M.D. Nadeem Abu-Rustum, M.D. Yukio Sonoda, M.D. Jae
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan
More informationCo-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG
OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery
More informationCAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?
CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA? M. Modarres-Gilani *1, F. Ghaemmaghami 1, S. Ansaripoor 1, M. Shariat 2 and F. Zaeri 3 1)
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationAHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following
AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationSurgical Cytoreduction in Ovarian Cancer
Review Article [1] May 01, 2004 Ovarian Cancer [2], Oncology Journal [3] By Wayne A. Mccreath, MD [4] and Dennis S. Chi, MD [5] The majority of ovarian cancer patients present with advanced-stage disease,
More informationReview Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationStage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
Original Investigation 33 Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy Gökhan Boyraz, Derman Başaran, Mehmet
More informationPrediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
Original Article J Gynecol Oncol Vol. 22, No. 4:269-274 pissn 2005-0380 eissn 2005-0399 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationIntroduction. Abstract
Gynecologic Oncology 103 (2006) 1083 1090 www.elsevier.com/locate/ygyno The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationWomen s Imaging Original Research
Women s Imaging Original Research Lakhman et al. Postoperative CT as Prognostic Biomarker in Gynecologic Cancer Women s Imaging Original Research Yulia Lakhman 1 Oguz Akin 1 Michael J. Sohn 1 Junting Zheng
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationAscites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
Xu et al. Journal of Ovarian Research (2016) 9:85 DOI 10.1186/s13048-016-0294-z RESEARCH Open Access Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage
More informationOvarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?
Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial
More informationSignificance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma
ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationClinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
Qin et al. Journal of Ovarian Research (2018) 11:49 https://doi.org/10.1186/s13048-018-0422-z RESEARCH Open Access Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment
More informationIntraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
The new england journal of medicine original article Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Deborah K. Armstrong, M.D., Brian Bundy, Ph.D., Lari Wenzel, Ph.D., Helen Q. Huang, M.S.,
More informationBiological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report
ONCOLOGY LETTERS 9: 1239-1243, 2015 Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report SHIGAO HUANG *, YAZHENG
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER FOLLOWED BY COMPLETE REMISSION AFTER ADJUVANT CHEMOTHERAPY
ORIGINAL ARTICLE Obstet Gynecol Sci 2013;56(1):29-35 http://dx.doi.org/10.5468/ogs.2013.56.1.29 pissn 2287-8572 eissn 2287-8580 PROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN
More informationOutcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationOriginal Article. Management of Ovarian Cancer: Experience of a single Institution. Elkhouly. E.¹, Abdelghany. A.¹, Rageh. T. 2 and Shehata. M.
Original Article Kasr El-aini J. Clin. Oncol. nucl. med. vol. 10, no. 1-2, Jan.-April. 2014:12-17 Management of Ovarian Cancer: Experience of a single Institution Elkhouly. E.¹, Abdelghany. A.¹, Rageh.
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-017-0241-1 December 2017, Vol. 3, No. 6, P P ORIGINAL ARTICLE Comparative analysis of ATP-based tumor chemosensitivity assay-directed chemotherapy
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More information7. Cytoreductive surgery in endometrial cancer and uterine sarcomas
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationOvarian cancer experience from a Romanian regional center: preliminary results
Human & Veterinary Medicine International Journal of the Bioflux Society OPEN ACCESS Research Article Ovarian cancer experience from a Romanian regional center: preliminary results 1 Anita-Roxana Maxim,
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationGynecologic Oncology
Gynecologic Oncology 124 (2012) 10 14 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno An analysis of patients with bulky advanced
More informationSecondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
original article Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma Peter G. Rose, M.D., Stacy Nerenstone, M.D., Mark F. Brady, Ph.D., Daniel Clarke-Pearson, M.D., George Olt, M.D., Stephen
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationIn the United States, ovarian cancer is the leading
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer Giovanni D. Aletti, MD, Sean C. Dowdy, MD, Bobbie S. Gostout, MD, Monica B. Jones, MD, C. Robert Stanhope, MD, Timothy
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationSetting The setting was secondary care. The economic study was carried out in Belgium.
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M Record
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationPrimary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz
Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz Epithelial Subtypes Serous Endometrioid Mucinous Transitional Clear Cell Mixed Undifferentiated Squamous Ovarian Surface Epithelium Naora et al.,
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationOvarian cancer in elderly women
Ovarian cancer Ovarian cancer in elderly women Claire FALANDRY, Michel FABBRO, Olivier GUERIN, Jean-Emmanuel KURTZ, Anne LESOIN. Problem Background Population on the rise and extremely heterogeneous Delayed
More informationsymposium article Optimal primary therapy of ovarian cancer M. A. Bookman* introduction symposium article
Annals of Oncology 27 (Supplement 1): i58 i62, 2016 doi:10.1093/annonc/mdw088 Optimal primary therapy of ovarian cancer M. A. Bookman* Arizona Oncology and US Oncology Research, Tucson, AZ, USA Background:
More informationAnshuma Bansal 1 Bhavana Rai
DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationImpact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationStudy population The study population comprised patients with the following characteristics:
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell
More informationA Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More information1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian
1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38(18):2435-45.
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More informationCONTRIBUTION. Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma
CONTRIBUTION Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma DAVID B. SEIFER, MD*; ALEXANDER W. KENNEDY, MD; KENNETH D. WEBSTER, MD; SHARON VANDERBRUG MEDENDORP, MPH;
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More information2007 Cancer Committee
2007 Cancer Committee Ovarian Cancer Study Stage III & IV Albert Bonebrake, MD Rosie Netzer, RHIT, CTR Joanne Schahuber, R.T.(R)(T)(M)(QM) Table of Contents Table of Contents... 1 Ovarian Cancer Facts:...
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationEFFECT OF AN ENHANCED RECOVERY AFTER SURGERY PROGRAM ON OPIOID USE AND PATIENT-REPORTED OUTCOMES
EFFECT OF AN ENHANCED RECOVERY AFTER SURGERY PROGRAM ON OPIOID USE AND PATIENT-REPORTED OUTCOMES Obstetrics & Gynecology Vol. 132, No. 2, August 2018 KUSMW OBGYN Journal Club Thomas Greaves, MD, PGY4 August
More informationNon-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data
ANTICANCER RESECH 26: 3175-3182 (2006) Non-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data D. MAURI, G. PENTHEROUDAKIS, D. BAFALOUKOS, D. PECTASIDES,
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More information